IκBζ protein holds potential for treating autoimmune conditions

NewsGuard 100/100 Score

Our immune system is remarkably powerful. It quickly assembles teams of cells to eliminate threats inside our bodies. But sometimes, it hits the wrong target. Autoimmune diseases like lupus and multiple sclerosis result from friendly fire-;immune cells attacking healthy tissues and organs by mistake. New treatments and therapeutic targets are direly needed for these conditions.

Now, Cold Spring Harbor Laboratory (CSHL) Professor Christopher Vakoc may have stumbled upon a new therapeutic target-;one hidden in plain sight. Vakoc and his team discovered that IκBζ, a well-studied protein in the immunology field, contains an overlooked sequence, which lets it activate key proteins in immune cells. While the sequence-;the OCA peptide-;is tiny, targeting it may have significant effects in reeling in immune cells gone haywire.

For years, IκBζ was known for one important job-;controlling NFκB, a protein that's crucial for mounting an immune response. But it turns out IκBζ has dual functions. Vakoc's team found it also activates another important family of immune proteins called POUs. And it does this through the OCA peptide. Firing up both immune reactions may ensure the quickest response to encroaching dangers-;a vital trademark of our natural defenses.

The immune system is held in check most of the time. But the moment a pathogen arrives, it needs to very quickly adapt. The ability to respond within seconds is critical to eliminating bacteria, an invading virus, or even cancer. Time is of the essence."

Christopher Vakoc, Professor, CSHL

Why has evolution assigned IκBζ this moonlight job? Vakoc suspects it has something to do with the enormous number of tasks immune systems perform. While immune cells activate many of the same proteins, each cell also has its own duties. The duality of IκBζ might provide our body's defenders the versatility to rapidly switch between roles.

"Evolution often finds creative and efficient solutions to problems in life," Vakoc explains. "We think the OCA peptide allows different types of immune cells to respond quickly, with the right genes at the right time and place. It's all about personalizing the immune response for different cells in the body."

The discovery might form the basis for future immunotherapies against autoimmune disorders. Since the OCA peptide is well-defined and found in many immune cells, it could make for a prime drug target. And that's where Vakoc will set his sights next.

"Targeting IκBζ via its OCA peptide would be expected to have interesting impacts on the immune system, with highly cell-type-specific effects," Vakoc says. "Our future research will explore this question."

Source:
Journal reference:

Alpsoy, A., et al. (2024). IκBζ is a dual-use coactivator of NF-κB and POU transcription factors. Molecular Cell. doi.org/10.1016/j.molcel.2024.01.007.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Maternal influences on food allergy prevention: A closer look at diet and environment